## Abemaciclib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to palbociclib for<br>Other specified malignant neoplasms of breast |

## Abiraterone

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Oral > Solid: 250 mg; 500 mg | Malignant neoplasms of prostate |

## Adalimumab

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease<br>- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL | Axial spondyloarthritis<br>Crohn disease site<br>Rheumatoid arthritis |

## Afatinib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to erlotinib for<br>Other specified malignant neoplasms of bronchus or lung |

## All-trans retinoic acid

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid: 10 mg capsule | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Allopurinol

| Section | Indications |
| --- | --- |
| Supportive medicines<br>- Parenteral > General injections > IV: 500 mg (as sodium) powder for injection<br>- Oral > Solid: 100 mg; 300 mg | Tumour lysis syndrome |

## Anastrozole

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Oral > Solid: 1 mg tablet | Malignant neoplasms of breast<br>Other specified malignant neoplasms of breast |

## Arsenic trioxide

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Asparaginase

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection<br>- Powder for injection: 10 000 IU in vial. | Lymphoid leukaemia, not elsewhere classified<br>Unspecified malignant neoplasms of unspecified sites |

## Atezolizumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion<br>- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion | Therapeutic equivalent to pembrolizumab for<br>Adenocarcinoma of stomach<br>Hepatocellular carcinoma of liver<br>Therapeutic equivalent to pembrolizumab for<br>Other specified malignant neoplasms of bronchus or lung<br>Other specified malignant neoplasms of bronchus or lung |

## Axicabtagene ciloleucel

| Section | Indications |
| --- | --- |
| Antineoplastics and supportive medicines<br>- Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight. | Diffuse large B-cell lymphomas |

## Axitinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid > tablet: 1 mg; 3 mg; 5 mg | Renal cell carcinoma of kidney, except renal pelvis |

## Azacitidine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 100 mg in vial powder for injection | Myeloid leukaemia |

## Azathioprine

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease<br>- Oral > Solid > tablet: 50 mg (scored)<br>- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)<br>- Oral > Liquid: 10 mg per mL<br>- Oral > Solid > tablet: 25 mg; 50 mg (scored) | Relapsing-remitting multiple sclerosis<br>Failure or rejection of transplanted organs or tissues |

## Bendamustine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL | Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Follicular lymphoma |

## Bevacizumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion | Hepatocellular carcinoma of liver |

## Bicalutamide

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Oral > Solid: 50 mg | Malignant neoplasms of prostate |

## Binimetinib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to trametinib for<br>Other specified melanoma of skin |

## Bleomycin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate) | Kaposi sarcoma of unspecified primary site<br>Germ cell tumour of testis<br>Other specified malignant neoplasms of the ovary<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma |

## Blinatumomab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial | B lymphoblastic leukaemia or lymphoma, not elsewhere classified |

## Bortezomib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection | Plasma cell myeloma |

## Calcium folinate (leucovorin calcium)

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule<br>- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg<br>- Oral > Solid: 15 mg tablet<br>- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule | Burkitt lymphoma including Burkitt leukaemia<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of rectum<br>Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of colon<br>Unspecified malignant neoplasms of unspecified sites<br>Malignant trophoblastic neoplasms of placenta |

## Capecitabine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Oral > Solid > tablet: 150 mg; 500 mg | Malignant neoplasms of rectum<br>Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of colon<br>Other specified malignant neoplasms of breast |

## Carboplatin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL | Other specified gliomas of brain<br>Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx<br>Malignant neoplasms of cervix uteri<br>Malignant neoplasms of hypopharynx<br>Malignant neoplasms of nasopharynx<br>Malignant neoplasms of oropharynx<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Other specified malignant neoplasms of the ovary<br>Germ cell tumour of testis<br>Malignant neoplasms of nasopharynx<br>Other specified carcinomas of ovary<br>Other specified malignant neoplasms of bronchus or lung<br>Malignant neoplasms of breast<br>Retinoblastoma<br>Malignant neoplasms of kidney, except renal pelvis |

## Cemiplimab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion | Therapeutic equivalent to pembrolizumab for<br>Adenocarcinoma of stomach<br>Therapeutic equivalent to pembrolizumab for<br>Other specified malignant neoplasms of bronchus or lung<br>Other specified malignant neoplasms of bronchus or lung |

## Certolizumab pegol

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease | Therapeutic equivalent to adalimumab for<br>Axial spondyloarthritis<br>Therapeutic equivalent to adalimumab for<br>Crohn disease site<br>Therapeutic equivalent to adalimumab for<br>Rheumatoid arthritis |

## Chlorambucil

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Oral > Solid: 2 mg tablet | Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Unspecified malignant neoplasms of unspecified sites |

## Ciclosporin

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease<br>◦ Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection<br>◦ Oral > Liquid: 100 mg per mL<br>◦ Oral > Solid > capsule: 25 mg | Failure or rejection of transplanted organs or tissues |

## Cisplatin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL<br>◦ Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL<br>◦ Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection | Other specified gliomas of brain<br>Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx<br>Malignant neoplasms of cervix uteri<br>Malignant neoplasms of hypopharynx<br>Malignant neoplasms of oropharynx<br>Malignant neoplasms of nasopharynx<br>Germ cell tumour of testis<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Other specified malignant neoplasms of the ovary<br>Malignant neoplasms of nasopharynx<br>Other specified malignant neoplasms of bronchus or lung<br>Unspecified malignant neoplasms of unspecified sites |

## Cladribine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial | Langerhans cell histiocytosis |

## Cobimetinib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to trametinib for<br>Other specified melanoma of skin |

## Crizotinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid > capsule: 200 mg; 250 mg<br>◦ Oral > Solid: 200 mg; 250 mg | Anaplastic large cell lymphoma, ALK-positive<br>Other specified malignant neoplasms of bronchus or lung |

## Cyclophosphamide

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection<br>◦ Oral > Solid > dosage form: 25 mg; 50 mg<br>◦ Oral > Solid: 25 mg tablet<br>◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection | Diffuse large B-cell lymphoma, not otherwise specified<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Plasma cell myeloma<br>Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Other specified gliomas of brain<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Rhabdomyosarcoma primary site<br>Malignant neoplasms of breast<br>Other specified malignant neoplasms of breast<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma<br>Malignant trophoblastic neoplasms of placenta<br>Follicular lymphoma<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis |

## Cytarabine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial<br>◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection | Acute myeloid leukaemia with recurrent genetic abnormalities<br>Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Myeloid leukaemia<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Langerhans cell histiocytosis<br>Unspecified malignant neoplasms of unspecified sites |

## Dabrafenib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid: 50 mg; 75 mg | Other specified melanoma of skin |

## Dacarbazine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection | Hodgkin lymphoma |

## Dactinomycin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 500 µg in vial powder for injection | Rhabdomyosarcoma primary site<br>Unspecified malignant neoplasms of unspecified sites<br>Malignant trophoblastic neoplasms of placenta<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis |

## Daratumumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL | Plasma cell myeloma |

## Darbepoetin alfa

| Section | Indications |
| --- | --- |
| Supportive medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br>Drug-induced aplastic anaemia |

## Dasatinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet | Chronic myelogenous leukaemia, BCR-ABL1-positive |

## Daunorubicin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride) | Acute myeloid leukaemia with recurrent genetic abnormalities<br>Lymphoid leukaemia, not elsewhere classified<br>Myeloid leukaemia |

## Dexamethasone

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>◦ Oral > Liquid: 2 mg per 5 mL<br>◦ Oral > Solid: 2 mg; 4 mg<br>◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)<br>◦ Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)<br>◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)<br>◦ Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)<br>◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base<br>◦ Oral > Solid > tablet: 4 mg (as dexamethasone base) | Anaplastic large cell lymphoma, ALK-negative<br>Lymphoid leukaemia, not elsewhere classified<br>Plasma cell myeloma<br>Burkitt lymphoma including Burkitt leukaemia<br>Anaplastic large cell lymphoma, ALK-positive |

## Docetaxel

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL | Malignant neoplasms of breast<br>Other specified malignant neoplasms of breast<br>Unspecified malignant neoplasms of unspecified sites<br>Malignant neoplasms of prostate |

## Dostarlimab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion | Other specified malignant neoplasms of corpus uteri |

## Doxorubicin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)<br>◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride) | Diffuse large B-cell lymphoma, not otherwise specified<br>Plasma cell myeloma<br>Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Rhabdomyosarcoma primary site<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Kaposi sarcoma of unspecified primary site<br>Malignant neoplasms of breast<br>Other specified malignant neoplasms of breast<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma<br>Follicular lymphoma<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis |

## Doxorubicin (as pegylated liposomal)

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) | Kaposi sarcoma of unspecified primary site |

## Durvalumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion | Hepatocellular carcinoma of liver<br>Malignant neoplasms of biliary tract, distal bile duct<br>Malignant neoplasm of intrahepatic bile ducts<br>Malignant neoplasms of gallbladder<br>Malignant neoplasms of proximal biliary tract, cystic duct<br>Other specified malignant neoplasms of bronchus or lung |

## Encorafenib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to dabrafenib for<br>Other specified melanoma of skin |

## Enzalutamide

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>◦ Oral > Solid: 40 mg | Therapeutic equivalent to abiraterone for<br>Malignant neoplasms of prostate<br>Malignant neoplasms of prostate |

## Epoetin alfa

| Section | Indications |
| --- | --- |
| Supportive medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br>Drug-induced aplastic anaemia |

## Epoetin beta

| Section | Indications |
| --- | --- |
| Supportive medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br>Drug-induced aplastic anaemia |

## Erlotinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid: 100 mg; 150 mg | Other specified malignant neoplasms of bronchus or lung |

## Erythropoiesis-stimulating agents

| Section | Indications |
| --- | --- |
| Supportive medicines<br>◦ Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose) | Drug-induced aplastic anaemia |

## Etanercept

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease | Therapeutic equivalent to adalimumab for<br>Axial spondyloarthritis<br>Therapeutic equivalent to adalimumab for<br>Crohn disease site<br>Therapeutic equivalent to adalimumab for<br>Rheumatoid arthritis |

## Etoposide

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)<br>◦ Oral > Solid: 100 mg capsule; 50 mg capsule<br>◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule<br>◦ Oral > Solid: 100 mg capsule | Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Myeloid leukaemia<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Germ cell tumour of testis<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Other specified malignant neoplasms of the ovary<br>Other specified malignant neoplasms of bronchus or lung<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma<br>Malignant trophoblastic neoplasms of placenta<br>Retinoblastoma<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis |

## Everolimus

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg<br>◦ Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg | Other specified gliomas of brain |

## Filgrastim

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial | Acquired neutropaenia |

## Fingolimod

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease<br>- Oral > Solid: 0.25 mg; 0.5 mg | Relapsing-remitting multiple sclerosis |

## Fludarabine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection<br>- Oral > Solid: 10 mg tablet (fludarabine phosphate) | Chronic lymphocytic leukaemia or small lymphocytic lymphoma |

## Fluorouracil

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 50 mg per mL in vial<br>- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule | Malignant neoplasms of nasopharynx<br>Malignant neoplasms of rectum<br>Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of breast<br>Malignant neoplasms of colon<br>Unspecified malignant neoplasms of unspecified sites |

## Flutamide

| Section | Indications |
| --- | --- |
| Hormones and antihormones | Therapeutic equivalent to bicalutamide for<br>Malignant neoplasms of prostate |

## Fulvestrant

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Parenteral > General injections > IV: 250 mg per 5 mL | Malignant neoplasms of breast |

## Gefitinib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to erlotinib for<br>Other specified malignant neoplasms of bronchus or lung |

## Gemcitabine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection | Other specified carcinomas of ovary<br>Other specified malignant neoplasms of bronchus or lung |

## Golimumab

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease | Therapeutic equivalent to adalimumab for<br>Axial spondyloarthritis<br>Therapeutic equivalent to adalimumab for<br>Crohn disease site<br>Therapeutic equivalent to adalimumab for<br>Rheumatoid arthritis |

## Goserelin

| Section | Indications |
| --- | --- |
| Hormones and antihormones | Therapeutic equivalent to leuprorelin for<br>Malignant neoplasms of breast<br>Therapeutic equivalent to leuprorelin for<br>Malignant neoplasms of prostate |

## Hydrocortisone

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate) | Lymphoid leukaemia, not elsewhere classified<br>Burkitt lymphoma including Burkitt leukaemia<br>Unspecified malignant neoplasms of unspecified sites |

## Hydroxyurea (hydroxycarbamide)

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g<br>◦ Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg | Squamous cell carcinoma of oropharynx<br>Chronic myeloid leukaemia, not elsewhere classified |

## Ibrutinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid: 140 mg | Chronic lymphocytic leukaemia or small lymphocytic lymphoma |

## Ifosfamide

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection<br>◦ Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection | Burkitt lymphoma including Burkitt leukaemia<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Rhabdomyosarcoma primary site<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Germ cell tumour of testis<br>Other specified malignant neoplasms of the ovary<br>Unspecified malignant neoplasms of unspecified sites<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis |

## Imatinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid: 100 mg; 400 mg | B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1<br>Chronic myeloid leukaemia, not elsewhere classified<br>Gastrointestinal stromal tumour of unspecified gastrointestinal sites |

## Infliximab

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease | Therapeutic equivalent to adalimumab for<br>Axial spondyloarthritis<br>Therapeutic equivalent to adalimumab for<br>Crohn disease site<br>Therapeutic equivalent to adalimumab for<br>Rheumatoid arthritis |

## Ipilimumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion | Renal cell carcinoma of kidney, except renal pelvis<br>Squamous cell carcinoma of oesophagus<br>Melanoma of skin<br>Other specified malignant neoplasms of bronchus or lung |

## Irinotecan

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial | Rhabdomyosarcoma primary site<br>Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of kidney, except renal pelvis |

## Lenalidomide

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Oral > Solid: 25 mg | Plasma cell myeloma |

## Lenvatinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid > capsule: 4 mg; 10 mg | Renal cell carcinoma of kidney, except renal pelvis |

## Leuprorelin

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>◦ Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe | Malignant neoplasms of breast<br>Malignant neoplasms of prostate |

## Lisocabtagene maraleucel

| Section | Indications |
| --- | --- |
| Antineoplastics and supportive medicines | Therapeutic equivalent to axicabtagene ciloleucel for<br>Diffuse large B-cell lymphomas |

## Melphalan

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 50 mg in vial powder for injection<br>◦ Oral > Solid: 2 mg | Plasma cell myeloma |

## Mercaptopurine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Oral > Liquid: 20 mg per mL<br>◦ Oral > Solid: 50 mg tablet | Lymphoid leukaemia, not elsewhere classified<br>Acute myeloid leukaemia with recurrent genetic abnormalities<br>Langerhans cell histiocytosis<br>Unspecified malignant neoplasms of unspecified sites |

## Mesna

| Section | Indications |
| --- | --- |
| Supportive medicines<br>◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule<br>◦ Oral > Solid > tablet: 400 mg; 600 mg<br>◦ Oral > Other: 600 mg<br>◦ Oral > Solid > tablet: 400 mg<br>◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule<br>◦ Oral > Solid: 400 mg; 600 mg | Rhabdomyosarcoma primary site<br>Germ cell tumour of testis<br>Other specified malignant neoplasms of the ovary<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Unspecified malignant neoplasms of unspecified sites<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis<br>Burkitt lymphoma including Burkitt leukaemia |

## Methotrexate

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection<br>◦ Oral > Solid: 2.5 mg (as sodium salt)<br>◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt) | Lymphoid leukaemia, not elsewhere classified<br>Acute myeloid leukaemia with recurrent genetic abnormalities<br>Burkitt lymphoma including Burkitt leukaemia<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Langerhans cell histiocytosis<br>Osteosarcoma of bone or articular cartilage of unspecified sites<br>Malignant neoplasms of breast<br>Unspecified malignant neoplasms of unspecified sites<br>Malignant trophoblastic neoplasms of placenta |
| Immunomodulators for non-malignant disease<br>◦ Parenteral > General injections > SC: pre-filled syringe in multiple strengths | Crohn disease site<br>Psoriatic arthritis |

## Methylprednisolone

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)<br>◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection | Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified |

## Nilotinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid > capsule: 150 mg; 200 mg | Chronic myelogenous leukaemia, BCR-ABL1-positive |

## Nilutamide

| Section | Indications |
| --- | --- |
| Hormones and antihormones | Therapeutic equivalent to bicalutamide for<br>Malignant neoplasms of prostate |

## Nivolumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>◦ Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion<br>◦ Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion<br>◦ Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion | Therapeutic equivalent to pembrolizumab for<br>Melanoma of skin<br>Melanoma of skin<br>Renal cell carcinoma of kidney, except renal pelvis<br>Squamous cell carcinoma of oesophagus<br>Adenocarcinoma of oesophagogastric junction<br>Adenocarcinoma of stomach<br>Other specified malignant neoplasms of bronchus or lung |

## Osimertinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate) | Other specified malignant neoplasms of bronchus or lung |

## Oxaliplatin

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial | Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of colon |

## Paclitaxel

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 6 mg per mL | Malignant neoplasms of cervix uteri<br>Kaposi sarcoma of unspecified primary site<br>Other specified malignant neoplasms of the ovary<br>Malignant neoplasms of nasopharynx<br>Other specified carcinomas of ovary<br>Other specified malignant neoplasms of bronchus or lung<br>Other specified malignant neoplasms of breast<br>Malignant neoplasms of breast |

## Palbociclib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid: 75 mg; 100 mg; 125 mg | Other specified malignant neoplasms of breast |

## Panitumumab

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial | Other specified malignant neoplasms of large intestine |

## Pegaspargase

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection | Lymphoid leukaemia, not elsewhere classified |

## Pegfilgrastim

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe | Acquired neutropaenia |

## Pembrolizumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial<br>- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion<br>- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection | Melanoma of skin<br>Other specified malignant neoplasms of large intestine<br>Malignant neoplasms of cervix uteri<br>Adenocarcinoma of stomach<br>Malignant neoplasms of oesophagogastric junction<br>Squamous cell carcinoma of hypopharynx and variants<br>Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx<br>Squamous cell carcinoma of oropharynx<br>Squamous cell carcinoma of nasopharynx<br>Therapeutic equivalent to nivolumab for<br>Melanoma of skin<br>Renal cell carcinoma of kidney, except renal pelvis<br>Carcinoma of breast, specialised type<br>Squamous cell carcinoma of oesophagus<br>Other specified malignant neoplasms of bronchus or lung |

## Pertuzumab

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution | Carcinoma of breast, specialised type |

## Prednisolone

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>◦ Oral > Liquid: 5 mg per mL<br>◦ Oral > Solid: 5 mg; 25 mg | Lymphoid leukaemia, not elsewhere classified<br>Diffuse large B-cell lymphoma, not otherwise specified<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Plasma cell myeloma<br>Burkitt lymphoma including Burkitt leukaemia<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Langerhans cell histiocytosis<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma<br>Malignant neoplasms of prostate<br>Follicular lymphoma |

## Prednisone

| Section | Indications |
| --- | --- |
| Hormones and antihormones | Therapeutic equivalent to prednisolone for<br>Lymphoid leukaemia, not elsewhere classified<br>Therapeutic equivalent to prednisolone for<br>Diffuse large B-cell lymphoma, not otherwise specified<br>Therapeutic equivalent to prednisolone for<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Therapeutic equivalent to prednisolone for<br>Plasma cell myeloma<br>Therapeutic equivalent to prednisolone for<br>Anaplastic large cell lymphoma, ALK-negative<br>Therapeutic equivalent to prednisolone for<br>Anaplastic large cell lymphoma, ALK-positive<br>Therapeutic equivalent to prednisolone for<br>Langerhans cell histiocytosis<br>Therapeutic equivalent to prednisolone for<br>Hodgkin lymphoma<br>Therapeutic equivalent to prednisolone for<br>Malignant neoplasms of prostate<br>Therapeutic equivalent to prednisolone for<br>Follicular lymphoma |

## Procarbazine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Oral > Solid: 50 mg (as hydrochloride)<br>◦ Oral > Solid > capsule: 50 mg (as hydrochloride) | Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma |

## Rasburicase

| Section | Indications |
| --- | --- |
| Supportive medicines<br>◦ Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution | Tumour lysis syndrome |

## Realgar-indigo naturalis formulation

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg) | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Ribociclib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to palbociclib for<br>Other specified malignant neoplasms of breast |

## Rituximab

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial | Diffuse large B-cell lymphoma, not otherwise specified<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Burkitt lymphoma including Burkitt leukaemia<br>Follicular lymphoma |

## Tacrolimus

| Section | Indications |
| --- | --- |
| Immunomodulators for non-malignant disease<br>- Parenteral > General injections > IV: 5 mg per mL in 1 mL vial<br>- Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension<br>- Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release) | Failure or rejection of transplanted organs or tissues |

## Tamoxifen

| Section | Indications |
| --- | --- |
| Hormones and antihormones<br>- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate) | Malignant neoplasms of breast<br>Other specified malignant neoplasms of breast |

## Temozolomide

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Parenteral > General injections > IV: 100 mg in vial powder for injection<br>- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg | Other specified gliomas of brain<br>Neuroblastoma, NOS<br>Unspecified malignant neoplasms of unspecified sites<br>Ewing sarcoma of bone or articular cartilage of unspecified sites |

## Thalidomide

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Oral > Solid: 50 mg | Plasma cell myeloma |

## Tioguanine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>- Oral > Solid: 40 mg | Lymphoid leukaemia, not elsewhere classified |

## Tisagenlecleucel

| Section | Indications |
| --- | --- |
| Antineoplastics and supportive medicines | Therapeutic equivalent to axicabtagene ciloleucel for<br>Diffuse large B-cell lymphomas |

## Tislelizumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 100 mg per 10 mL<br>- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion<br>- Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion | Malignant neoplasms of urinary tract<br>Squamous cell carcinoma of oesophagus<br>Other specified malignant neoplasms of bronchus or lung<br>Hodgkin lymphoma |

## Toripalimab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 240 mg per 6 mL in vial | Squamous cell carcinoma of oesophagus<br>Malignant neoplasms of nasopharynx |

## Trametinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Oral > Solid: 0.5 mg; 2 mg | Other specified melanoma of skin |

## Trastuzumab

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection | Carcinoma of breast, specialised type |

## Trastuzumab emtansine

| Section | Indications |
| --- | --- |
| Targeted therapies<br>- Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection | Carcinoma of breast, specialised type |

## Tremelimumab

| Section | Indications |
| --- | --- |
| Immunomodulators<br>- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion | Hepatocellular carcinoma of liver<br>Other specified malignant neoplasms of bronchus or lung |

## Triptorelin

| Section | Indications |
| --- | --- |
| Hormones and antihormones | Therapeutic equivalent to leuprorelin for<br>Malignant neoplasms of breast<br>Therapeutic equivalent to leuprorelin for<br>Malignant neoplasms of prostate |

## Vemurafenib

| Section | Indications |
| --- | --- |
| Targeted therapies | Therapeutic equivalent to dabrafenib for<br>Other specified melanoma of skin |

## Vinblastine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)<br>◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) | Other specified gliomas of brain<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Langerhans cell histiocytosis<br>Kaposi sarcoma of unspecified primary site<br>Germ cell tumour of testis<br>Other specified malignant neoplasms of the ovary<br>Unspecified malignant neoplasms of unspecified sites<br>Hodgkin lymphoma |

## Vincristine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)<br>◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) | Other specified gliomas of brain<br>Diffuse large B-cell lymphoma, not otherwise specified<br>Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Langerhans cell histiocytosis<br>Kaposi sarcoma of unspecified primary site<br>Rhabdomyosarcoma primary site<br>Hodgkin lymphoma<br>Unspecified malignant neoplasms of unspecified sites<br>Malignant trophoblastic neoplasms of placenta<br>Follicular lymphoma<br>Ewing sarcoma of bone or articular cartilage of unspecified sites<br>Retinoblastoma<br>Malignant neoplasms of kidney, except renal pelvis |

## Vinorelbine

| Section | Indications |
| --- | --- |
| Cytotoxic medicines<br>◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial<br>◦ Oral > Solid > capsule: 20 mg; 30 mg; 80 mg<br>◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial | Rhabdomyosarcoma primary site<br>Other specified malignant neoplasms of bronchus or lung<br>Other specified malignant neoplasms of breast |

## Zanubrutinib

| Section | Indications |
| --- | --- |
| Targeted therapies<br>◦ Oral > Solid: 80 mg<br>◦ Oral > Solid > capsule: 80 mg | Mantle cell lymphoma<br>Therapeutic equivalent to ibrutinib for<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma |

## Zoledronic acid

| Section | Indications |
| --- | --- |
| Supportive medicines<br>◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle | Malignant neoplasm metastasis in bone or bone marrow |